Mainz Biomed N.V. (MYNZ)
NASDAQ: MYNZ · Real-Time Price · USD
1.160
-0.030 (-2.52%)
At close: Jan 16, 2026, 4:00 PM EST
1.150
-0.010 (-0.84%)
After-hours: Jan 16, 2026, 7:05 PM EST
Mainz Biomed Employees
As of December 31, 2024, Mainz Biomed had 26 total employees, including 19 full-time and 7 part-time employees. The number of employees decreased by 45 or -63.38% compared to the previous year.
Employees
26
Change (1Y)
-45
Growth (1Y)
-63.38%
Revenue / Employee
$25,382
Profits / Employee
-$729,658
Market Cap
10.51M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 26 | -45 | -63.38% |
| Dec 31, 2023 | 71 | 7 | 10.94% |
| Dec 31, 2022 | 64 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MYNZ News
- 4 days ago - Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting - GlobeNewsWire
- 2 months ago - Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America - GlobeNewsWire
- 2 months ago - Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025 - GlobeNewsWire
- 2 months ago - Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS) - GlobeNewsWire
- 3 months ago - Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project - GlobeNewsWire
- 4 months ago - Mainz Biomed Announces Registration of ColoAlert in the United Kingdom - GlobeNewsWire
- 5 months ago - Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert® - GlobeNewsWire
- 5 months ago - Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants - GlobeNewsWire